Cohort (LON:CHRT)

QUOTE AND NEWS
Clusterstock  Apr 6  Comment 
The above table comes from Bill McBride at Calculated risk, and it shows the changes to the populations of various age groups over the last six years. There's been a lot of talk about the declining Labor Force Participation Rate, and how much...
Benzinga  Apr 1  Comment 
In a report published Tuesday, MLV & Co analyst Vernon T. Bernardino reiterated a Buy rating and $20.00 price target on Galectin Therapeutics (NASDAQ: GALT). In the report, MLV & Co noted, ÔÇťAlbeit from 8 patients, an abundance of data support...
StreetInsider.com  Apr 1  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Arrowhead+Research+%28ARWR%29+Completes+Enrollment+in+First+Cohort+of+ARC-520+Phase+2a/9336197.html for the full story.
MedPage Today  Mar 31  Comment 
WASHINGTON (MedPage Today) -- Years after results from the original trial lowered the bar on eligibility for ICDs, the latest data from the MADIT-CRT cohort are likely to introduce yet another group of patients to device therapy, but this time in...
MedPage Today  Mar 29  Comment 
WASHINGTON (MedPage Today) -- Transcatheter aortic valve implantation (TAVI) with the CoreValve device improved survival compared with surgery in the high-risk pivotal trial cohort.
MedPage Today  Mar 27  Comment 
WASHINGTON (MedPage Today) -- Standing above the rest of the trials at the upcoming American College of Cardiology meeting here will be two in particular -- SYMPLICITY HTN-3 and the CoreValve U.S. Pivotal Trial high-risk cohort.
DailyFinance  Mar 19  Comment 
BEVERLY, MA -- (Marketwired) -- 03/19/14 -- Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announces today...
MedPage Today  Mar 17  Comment 
(MedPage Today) -- Primary androgen deprivation therapy offered no survival benefit to prostate cancer patients with localized disease who opted not to have surgery or radiation therapy, data from a large retrospective cohort showed.
TechCrunch  Feb 20  Comment 
Amplitude, a Y Combinator-backed mobile analytics service aiming to take on the likes of Flurry and Mixpanel by offering advanced features at more competitive prices, is officially making its public debut today ahead of YC's Demo Day. And the...
DailyFinance  Feb 19  Comment 
AURORA, ON -- (Marketwired) -- 02/18/14 -- Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient...





 


References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki